| # | Title | Journal | Year | Citations |
|---|
| 1 | The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data | Cancer Discovery | 2012 | 12,801 |
| 2 | Hallmarks of Cancer: New Dimensions | Cancer Discovery | 2022 | 3,214 |
| 3 | Fundamental Mechanisms of Immune Checkpoint Blockade Therapy | Cancer Discovery | 2018 | 2,128 |
| 4 | AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer | Cancer Discovery | 2014 | 1,655 |
| 5 | The Emergence of lncRNAs in Cancer Biology | Cancer Discovery | 2011 | 1,612 |
| 6 | Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy | Cancer Discovery | 2011 | 1,486 |
| 7 | Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research | Cancer Discovery | 2014 | 1,341 |
| 8 | Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak | Cancer Discovery | 2020 | 1,286 |
| 9 | AACR Project GENIE: Powering Precision Medicine through an International Consortium | Cancer Discovery | 2017 | 1,235 |
| 10 | The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints | Cancer Discovery | 2015 | 1,180 |
| 11 | Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy | Cancer Discovery | 2016 | 1,158 |
| 12 | Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts | Cancer Discovery | 2019 | 1,120 |
| 13 | The Basic Principles of Chimeric Antigen Receptor Design | Cancer Discovery | 2013 | 1,108 |
| 14 | STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma | Cancer Discovery | 2018 | 1,108 |
| 15 | Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy | Cancer Discovery | 2016 | 1,087 |
| 16 | Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors | Cancer Discovery | 2013 | 1,073 |
| 17 | Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy | Cancer Discovery | 2015 | 997 |
| 18 | Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations | Cancer Discovery | 2017 | 997 |
| 19 | Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells | Cancer Discovery | 2017 | 945 |
| 20 | MYC, Metabolism, and Cancer | Cancer Discovery | 2015 | 919 |
| 21 | Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors inALK-Rearranged Lung Cancer | Cancer Discovery | 2016 | 919 |
| 22 | Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse | Cancer Discovery | 2017 | 881 |
| 23 | EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib | Cancer Discovery | 2012 | 852 |
| 24 | Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy | Cancer Discovery | 2014 | 836 |
| 25 | The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression | Cancer Discovery | 2018 | 834 |
| 26 | Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets | Cancer Discovery | 2015 | 821 |
| 27 | The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients | Cancer Discovery | 2020 | 820 |
| 28 | A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer | Cancer Discovery | 2011 | 818 |
| 29 | Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia | Cancer Discovery | 2016 | 811 |
| 30 | Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia | Cancer Discovery | 2016 | 799 |
| 31 | Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade | Cancer Discovery | 2016 | 785 |
| 32 | The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma | Cancer Discovery | 2014 | 782 |
| 33 | The BATTLE Trial: Personalizing Therapy for Lung Cancer | Cancer Discovery | 2011 | 778 |
| 34 | Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment | Cancer Discovery | 2019 | 778 |
| 35 | IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma | Cancer Discovery | 2019 | 778 |
| 36 | Cancer Cell Metabolism: One Hallmark, Many Faces | Cancer Discovery | 2012 | 773 |
| 37 | ceRNA Cross-Talk in Cancer: When ce-bling Rivalries Go Awry | Cancer Discovery | 2013 | 750 |
| 38 | Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine | Cancer Discovery | 2017 | 735 |
| 39 | Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets | Cancer Discovery | 2011 | 725 |
| 40 | The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer | Cancer Discovery | 2014 | 720 |
| 41 | Targeting CDK4 and CDK6: From Discovery to Therapy | Cancer Discovery | 2016 | 717 |
| 42 | Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer | Cancer Discovery | 2017 | 706 |
| 43 | Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling | Cancer Discovery | 2017 | 701 |
| 44 | Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer | Cancer Discovery | 2013 | 697 |
| 45 | Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities | Cancer Discovery | 2015 | 696 |
| 46 | Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer | Cancer Discovery | 2018 | 676 |
| 47 | Tumor Antigen Escape from CAR T-cell Therapy | Cancer Discovery | 2018 | 661 |
| 48 | Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer | Cancer Discovery | 2015 | 657 |
| 49 | Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1) | Cancer Discovery | 2017 | 647 |
| 50 | Therapeutic Targeting of the Tumor Microenvironment | Cancer Discovery | 2021 | 646 |
